<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03050684</url>
  </required_header>
  <id_info>
    <org_study_id>2016-162</org_study_id>
    <nct_id>NCT03050684</nct_id>
  </id_info>
  <brief_title>Does Vaginal Washing Affect the Success Rate of the Labour Induction?</brief_title>
  <official_title>Does Vaginal Washing Before Inserting Dinoprostone Affect the Success Rate of the Labour Induction?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeynep Kamil Maternity and Pediatric Research and Training Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeynep Kamil Maternity and Pediatric Research and Training Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators will use dinoprostone(Propess TM) for cervix ripening and labor induction in&#xD;
      term pregnant women.Vaginal pH base is achieved with the effect of hormones in pregnancy and&#xD;
      associated with this, vaginal infections rates increase. With the vaginal application of&#xD;
      Propess, the preparate remains in the vagina for a long time, with controlled&#xD;
      release,creating a film layer against bacteria and especially fungal infections and it was&#xD;
      thought that this could be a reason for unsuccessful birth induction by preventing release of&#xD;
      this ovule.&#xD;
&#xD;
      The aim of this study is to observe whether or not the rate of caesareans with the indication&#xD;
      of unsuccessful induction was reduced in patients by reducing the density of vaginal bacteria&#xD;
      and fungi with vaginal lavage and thereby increasing the effect of the drug and decreasing&#xD;
      the rate of unsuccessful inductions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include patients meeting the study criteria monitored in the delivery .&#xD;
&#xD;
      Verbal and written informed consent will be obtained from all patients before starting the&#xD;
      study. The patients will be randomised to 2 groups. In one group, vaginal lavage (the vagina&#xD;
      will first be washed with saline in a 20cc injector) will be applied then Propess will be&#xD;
      used and in the other group Propess will be used without any lavage.&#xD;
&#xD;
      It is planned to include 70 patients in each group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 20, 2017</start_date>
  <completion_date type="Actual">December 20, 2017</completion_date>
  <primary_completion_date type="Actual">December 10, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Controlled Study</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Succesful cervical repining which allows succesful vaginal delivery</measure>
    <time_frame>12 Months</time_frame>
    <description>Cervical ripening is defined cervical Bishop score &gt;5 the indication of unsuccessful induction</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Labor Induction</condition>
  <condition>Dinoprostone Vaginal Insert</condition>
  <condition>Vaginal Infection</condition>
  <condition>Effect Increased</condition>
  <arm_group>
    <arm_group_label>vaginal lavage group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>We will make vaginal lavage with steril %0.9 NaCl serum ( 20cc) before inserting dinoprostone (Propess ®) 10 mg vaginal ovule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>We will insert dinoprostone (Propess ®) vaginal ovule without vaginal lavage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>vaginal lavage group</intervention_name>
    <description>vaginal washing will be applied with steril %0.9 NaCl serum (20cc) before intravaginal PGE2 insertion.</description>
    <arm_group_label>vaginal lavage group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>vaginal washing will be not applied with steril %0.9 NaCl serum (20cc) before intravaginal PGE2 insertion.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with singleton pregnancies&#xD;
&#xD;
          -  Term gestational week (defined as&gt;37 weeks),&#xD;
&#xD;
          -  Fetal cephalic presentation&#xD;
&#xD;
          -  Participiants with with intact amniotic membrane&#xD;
&#xD;
          -  Reactive fetal heart rate&#xD;
&#xD;
          -  Cervical Modified Bishop's score &lt;5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with with multipl pregnancies&#xD;
&#xD;
          -  Participiants with malpresentation anomalies&#xD;
&#xD;
          -  Participiants with nonreassurring fetal heart rate&#xD;
&#xD;
          -  Participiants with more than three contractions in 10 minutes&#xD;
&#xD;
          -  Participiants with contrandications for using prostaglandins&#xD;
&#xD;
          -  Participiants with fetal anomaly&#xD;
&#xD;
          -  Participiants with fetal demise&#xD;
&#xD;
          -  Participiants with emercency delivery indications,&#xD;
&#xD;
          -  Participiants with previous cesarean delivery or have other uterine surgery&#xD;
&#xD;
          -  Participiants with cephalopelvic disproportion&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>İlter Yenidede, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zeynep Kamil Maternity and Children Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Çetin Kılıççı</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zeynep Kamil Maternity and Children Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zeynep Kamil Maternity and Children Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 21, 2017</study_first_submitted>
  <study_first_submitted_qc>February 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2017</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zeynep Kamil Maternity and Pediatric Research and Training Hospital</investigator_affiliation>
    <investigator_full_name>Çiğdem Yayla Abide</investigator_full_name>
    <investigator_title>Ob&amp;Gyn Specialist</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

